The way the price and reimbursement of medicines are determined
varies a lot between countries. In some countries price and
reimbursement are the result of negotiations between the
pharmaceutical manufacturer and the government; in other countries
negotiations involve insurance companies or intermediaries purchasing
medicines on behalf of their customers. And in some countries
governments make bulk purchases of medicine through so-called tender
orders, an auction-like process to which several companies are invited
to submit their best bid.
In the world’s poorest countries, we have made a special commitment
called our Access to Insulin Commitment, to improve access to
quality treatments for patients. We guarantee that we will provide
low-priced human insulin in 76 Least Developed Countries as defined by
the United Nations, other low-income countries as defined by the World
Bank and middle-income countries where large low-income populations
lack sufficient health coverage, as well as selected organisations
providing relief in humanitarian settings. Our guarantee entails that
we will provide human insulin in vials at a guaranteed ceiling price.
The ceiling price from 1 August 2020 is set at USD 3.00 per vial.